TARSUS PHARMACEUTICALS INC (TARS) Forecast, Price Target & Analyst Ratings
NASDAQ:TARS • US87650L1035
73.26 USD
-1.64 (-2.19%)
At close: Mar 6, 2026
73.26 USD
0 (0%)
After Hours: 3/6/2026, 8:00:02 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for TARSUS PHARMACEUTICALS INC (TARS).
Forecast Snapshot
Consensus Price Target
$93.20
+ 27.22% Upside
Next Earnings Forecast
Release DateApr 29, 2026
PeriodQ1 / 2026
EPS Estimate$0.02
Revenue Estimate153.64M
ChartMill Buy Consensus
88.00%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$93.20
Upside
+ 27.22%
From current price of $73.26 to mean target of $93.20, Based on 15 analyst forecasts
Low
$85.85
Median
$89.76
High
$105.00
Price Target Revisions
1 Month
5.16%
3 Months
9.90%
Price Target Summary
15 analysts have analysed TARS and the average price target is 93.2 USD. This implies a price increase of 27.22% is expected in the next year compared to the current price of 73.26.
The average price target has been revised upward by 9.9% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
88.00%
TARS was analyzed by 15 analysts. The buy percentage consensus is at 88. So analysts seem to be very confident about TARS.
In the previous month the buy percentage consensus was at a similar level.
TARS was analyzed by 15 analysts, which is quite many. So the average rating should be quite meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-25 | Guggenheim | Maintains | Buy -> Buy |
| 2026-02-25 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-12-09 | Barclays | Initiate | Overweight |
| 2025-11-20 | Mizuho | Initiate | Outperform |
| 2025-11-05 | Guggenheim | Maintains | Buy -> Buy |
| 2025-10-20 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-05-05 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2025-05-02 | Guggenheim | Maintains | Buy -> Buy |
| 2025-03-06 | Jefferies | Maintains | Buy -> Buy |
| 2025-02-26 | Guggenheim | Maintains | Buy -> Buy |
| 2025-02-26 | Barclays | Maintains | Overweight -> Overweight |
| 2025-02-26 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-24 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-02-10 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-01-27 | Barclays | Maintains | Overweight -> Overweight |
| 2025-01-22 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-11-15 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2024-11-14 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-08-09 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2024-05-13 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-05-10 | Barclays | Maintains | Overweight -> Overweight |
| 2024-05-09 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-03-06 | Jefferies | Maintains | Buy -> Buy |
| 2024-02-29 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2024-02-28 | Oppenheimer | Reiterate | Outperform -> Outperform |
Next Earnings Forecast Details
Next Earnings Details
Release DateApr 29, 2026
PeriodQ1 / 2026
EPS Estimate$0.02
Revenue Estimate153.64M
Revenue Q2Q96.13%
EPS Q2Q102.69%
Number of Analysts10
Next Earnings Revisions
Revenue (1 Month)
1.43%
Revenue (3 Months)
1.43%
EPS (1 Month)
4,162.50%
EPS (3 Months)
311.25%
Next Earnings Summary
TARS is expected to report earnings on 4/29/2026. The consensus EPS estimate for the next earnings is 0.02 USD and the consensus revenue estimate is 153.64M USD.
The next earnings revenue estimate has been revised upward by 1.43% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 17.447M -32.43% | 182.953M 948.62% | 451.36M 146.71% | 705.28M 56.26% | 892M 26.47% | 1.061B 18.95% | 1.223B 15.27% | 1.354B 10.71% | 1.534B 13.29% | 1.632B 6.39% | 1.712B 4.90% | |
| EBITDA YoY % growth | -142.281M -128.09% | -119.344M 16.12% | -69.153M 42.06% | -15.193M 78.03% | 153.67M 1,111.46% | 264.18M 71.91% | 705.74M 167.14% | 787.64M 11.60% | 854.66M 8.51% | 923.41M 8.04% | 1.028B 11.33% | |
| EBIT YoY % growth | -143.158M -128.29% | -120.569M 15.78% | -70.969M 41.14% | 75.517M 206.41% | 253.75M 236.02% | 401.32M 58.16% | 453.81M 13.08% | 620.38M 36.70% | 794.25M 28.03% | 875.43M 10.22% | 939.33M 7.30% | |
| Operating Margin | -820.53% | -65.90% | -15.72% | 10.71% | 28.45% | 37.82% | 37.11% | 45.82% | 51.78% | 53.64% | 54.87% | |
| EPS YoY % growth | -4.64 -81.96% | -3.10 33.19% | -1.62 47.74% | 0.71 143.62% | 3.34 373.33% | 5.92 76.88% | 6.78 14.66% | 8.30 22.31% | 10.40 25.41% | 11.57 11.18% | 12.80 10.63% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 0.02 102.69% | 0.15 130.30% | 0.53 277.21% | 0.73 465.16% | 0.64 3,636.65% | 0.98 573.35% | 1.06 99.54% | 1.23 68.99% |
| Revenue Q2Q % growth | 153.64M 96.13% | 171.22M 66.78% | 185.62M 56.38% | 190.7M 25.74% | 207.68M 35.17% | 230.07M 34.37% | 245.83M 32.44% | 260.66M 36.69% |
| EBITDA Q2Q % growth | 1.03M 103.99% | -2.693M 87.34% | 38.311M 391.21% | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | 2.782M 110.59% | 7.262M 132.74% | 29.502M 303.06% | 35.234M 541.75% | N/A | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
78.13%
EPS Next 5 Year
48.08%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
32.79%
Revenue Next 5 Year
24.47%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
79.44%
EBIT Next 5 Year
67.70%
TARSUS PHARMACEUTICALS INC / TARS Forecast FAQ
Can you provide the average price target for TARSUS PHARMACEUTICALS INC stock?
15 analysts have analysed TARS and the average price target is 93.2 USD. This implies a price increase of 27.22% is expected in the next year compared to the current price of 73.26.
What is the next earnings date for TARS stock?
TARSUS PHARMACEUTICALS INC (TARS) will report earnings on 2026-04-29.
Can you provide the consensus estimates for TARSUS PHARMACEUTICALS INC next earnings?
The consensus EPS estimate for the next earnings of TARSUS PHARMACEUTICALS INC (TARS) is 0.02 USD and the consensus revenue estimate is 153.64M USD.
What is the consensus rating for TARSUS PHARMACEUTICALS INC (TARS) stock?
The consensus rating for TARSUS PHARMACEUTICALS INC (TARS) is 88 / 100 . This indicates that analysts generally have a positive outlook on the stock.